Estándar de tratamiento en primera línea de cáncer de páncreas metastásico: ¿ABRAXANE-GEMCITABINA o FOLFIRINOX? - page 11

ASCO 2014: US Study Oncology Network,

OS comparative study

First line chemotherapy

Median OS

FOLFIRINOX

666

11.2 months

Gem + other drug

1567

7.0 months

Gem + nabpaclitaxel

184

10.2 months

Cartwright TH et al. J Clin Oncol 2014:32(15s):287s (Abs 4132)

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,2,3,4,5,6,7,8,9,10 12,13,14,15,16,17,18,19,20,21,...22